$256 million U.S. market opportunity drives expansion as company kicks off multi-channel promotional campaign
Scienture Holdings (SCNX) announced the official launch of commercial sales for Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL, marking a major milestone for the company as it transitions from development to full-scale commercialization. Arbli™ is the first FDA-approved, ready-to-use oral suspension formulation of losartan, offering a convenient and consistent treatment alternative for patients unable to take traditional solid dosage forms.
According to IQVIA data (MAT June 2025), the U.S. losartan market is valued at approximately $256 million annually, with over 71 million prescriptions written each year. Scienture sees this as a substantial market opportunity for Arbli™, which is expected to address a critical unmet need among patients who require flexible dosing options — particularly pediatric, geriatric, and dysphagic populations.
To accelerate adoption, Scienture has launched a multi-channel promotional campaign targeting healthcare professionals (HCPs) and institutional buyers. The company has also finalized multiple PBM-led and GPO agreements, securing formulary access and expanding commercial reach to more than 2,500 healthcare institutions across the United States. These include hospitals, clinics, nursing homes, specialty pharmacies, and long-term care facilities, representing potential penetration into nearly 20% of the institutional market.
“The start of commercial sales for Arbli™ represents a major achievement for Scienture as we move from innovation to execution,” said Narasimhan Mani, President and co-CEO of Scienture. Executive Chairman and co-CEO Shankar Hariharan added, “Arbli™ reflects our mission to deliver patient-focused pharmaceutical solutions that enhance accessibility and care. The early enthusiasm from healthcare providers underscores the strong market demand for this first-of-its-kind formulation.”
With commercial sales now underway, Scienture aims to build long-term growth through expanded awareness, institutional partnerships, and patient-centered value creation.
You might like this article:Earnings Season Heats Up as Tesla, Netflix, and Auto Giants Take Center Stage
